Table 3.
TEAEs and most frequent TEAEs (in ≥ 10% of all participants) by dosing cohort
| Summary of TEAEs, n (%) | 15 mg/kg (n = 10) |
30 mg/kg (n = 10) |
45 mg/kg (n = 10) |
Total (N = 30) |
|---|---|---|---|---|
| At least 1 TEAE | 8 (80.0) | 8 (80.0) | 7 (70.0) | 23 (76.7) |
| TRAEsa | 0 | 0 | 2 (20.0) | 2 (6.7) |
| Most frequent TEAEs (in ≥ 10% of all participants) by preferred terms | ||||
| Increased blood triglycerides | 1 (10.0) | 6 (60.0) | 3 (30.0) | 10 (33.3) |
| Increased blood glucose | 4 (40.0) | 0 | 2 (20.0) | 6 (20.0) |
| Increased blood uric acid | 2 (20.0) | 2 (20.0) | 2 (20.0) | 6 (20.0) |
| Increased blood creatine phosphokinase | 0 | 2 (20.0) | 2 (20.0) | 4 (13.3) |
aAs assessed by investigator
TEAE treatment-emergent adverse event, TRAE treatment-related adverse event